| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |